CEP-37440 is primarily investigated for its potential in cancer treatment, particularly as a targeted therapy. It functions as an inhibitor of focal adhesion kinase (FAK), a protein involved in cell adhesion, migration, and survival, which are critical processes in cancer progression. By blocking FAK, CEP-37440 aims to disrupt tumor growth, metastasis, and resistance to other therapies. It is being studied in preclinical and clinical trials for its efficacy in various solid tumors, including breast, lung, and pancreatic cancers. Its application could offer a novel approach to treating aggressive cancers that are difficult to manage with conventional therapies.